子宫内膜癌中的端粒酶逆转录酶启动子突变与基因扩增
从1944例子宫内膜癌中识别出66例端粒酶逆转录酶(TERT)改变(突变或扩增)的肿瘤,占3%。TERT改变肿瘤富集于拷贝数高/TP53异常分子亚型及TP53、CDKN2A/B、DROSHA体细胞突变,且独立预测更差的无进展生存和总生存。
要点
- TERT改变见于3%的子宫内膜癌,以拷贝数高/TP53异常亚型最常见(60%)。
- TERT扩增与TERT突变分子特征不同,TERT扩增基因组更不稳定且更常伴TP53和PPP2R1A改变。
- TERT改变与更差的无进展生存(中位18.7 vs 80.9个月,HR 0.33)和总生存(中位46.7个月 vs 未达到,HR 0.24)相关。
核心结论
- TERT改变的子宫内膜癌虽少见,但富集于拷贝数高/TP53异常肿瘤及TP53、CDKN2A/B和DROSHA体细胞突变,并独立预测更差的生存结局。
研究设计与样本
- 从2016年8月至2021年12月接受临床肿瘤-正常测序的1944例子宫内膜癌中识别携带体细胞TERT启动子热点突变或基因扩增的肿瘤。
- 评估TERT改变型与TERT野生型子宫内膜癌的临床病理变量、体细胞突变谱和生存结局。
主要发现
- 共识别66例TERT改变子宫内膜癌(43例TERT突变,23例TERT扩增),占未选择子宫内膜癌的3%。
- TERT改变子宫内膜癌以拷贝数高/TP53异常分子亚型最常见(n=40,60%),其次为微卫星不稳定(MSI-H)或拷贝数低/无特定分子谱(NSMP)(各n=13,20%)。
- TERT扩增与TERT突变子宫内膜癌分子特征不同,TERT扩增基因组更不稳定且更常伴TP53和PPP2R1A改变(q<0.1)。
- 与TERT野生型相比,TERT改变子宫内膜癌更常见拷贝数高/TP53异常分子亚型(31% vs 57%,p=0.001)和浆液性组织学(10% vs 26%,p=0.004),并显著富集TP53、CDKN2A/B和DROSHA体细胞遗传改变(q<0.1)。
- TERT改变患者中位无进展生存18.7个月(95%CI 11.8-不可估计[NE]),TERT野生型80.9个月(65.8-NE)(HR 0.33,95%CI 0.21-0.51,p<0.001);TERT改变患者中位总生存46.7个月(95%CI 30-NE),TERT野生型未达到(HR 0.24,95%CI 0.13-0.44,p<0.001)。
关键数值与推荐
- TERT改变型与TERT野生型拷贝数高/TP53异常分子亚型比例分别为57%和31%(p=0.001)。
- TERT改变型与TERT野生型浆液性组织学比例分别为26%和10%(p=0.004)。
- TERT改变型与TERT野生型中位无进展生存分别为18.7个月和80.9个月(HR 0.33,95%CI 0.21-0.51,p<0.001)。
- TERT改变型与TERT野生型中位总生存分别为46.7个月和未达到(HR 0.24,95%CI 0.13-0.44,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the clinicopathologic, molecular profiles, and survival outcomes of patients with endometrial carcinomas (ECs) harboring telomerase reverse transcriptase (TERT) hotspot mutations or gene amplification. METHODS: ECs harboring somatic TERT promoter hotspot mutations or gene amplification (TERT-altered) were identified from 1944 ECs that underwent clinical tumor-normal sequencing from 08/2016-12/2021. Clinicopathologic variables, somatic mutation profiles, and survival outcomes of TERT-alt and TERT-wild-type EC were assessed. RESULTS: We identified 66 TERT-altered ECs (43 TERT-mutated and 23 TERT-amplified), representing 3% of the unselected ECs across histologic subtypes. Most TERT-altered ECs were of copy number (CN)-high/TP53abn molecular subtype (n = 40, 60%), followed by microsatellite-unstable (MSI-H) or CN-low/no specific molecular profile (NSMP)(n = 13, 20% each). TERT-amplified and TERT-mutated ECs were molecularly distinct, with TERT-amplified ECs being more genomically instable and more frequently harboring TP53 and PPP2R1A alterations (q < 0.1). Compared to TERT-wild-type ECs, TERT-altered ECs were more commonly of CN-H/TP53abn molecular subtype (31% vs 57%, p = 0.001), serous histology (10% vs 26%, p = 0.004), and were significantly enriched for TP53, CDKN2A/B, and DROSHA somatic genetic alterations (q < 0.1). Median progression-free survival was 18.7 months (95% CI 11.8-not estimable [NE]) for patients with TERT-altered EC and 80.9 months (65.8-NE) for patients with TERT-wild-type EC (HR 0.33, 95% CI 0.21-0.51, p < 0.001). Similarly, median overall survival was 46.7 months (95% CI 30-NE) for TERT-altered EC patients and not reached for TERT-wild-type EC patients (HR 0.24, 95% CI 0.13-0.44, p < 0.001). CONCLUSION: TERT-altered ECs, although rare, are enriched for CN-high/TP53abn tumors, TP53, CDKN2A/B and DROSHA somatic mutations, and independently predict worse survival outcomes.
引用
- Praiss AM, Marra A, Zhou Q, et al. TERT promoter mutations and gene amplification in endometrial cancer. Gynecol Oncol. 2023. PMID: 37890416. doi:10.1016/j.ygyno.2023.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。